Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ORIC

ORIC Pharmaceuticals Inc

Jul 26 • 04:00PM ET

11.90

Dollar change +0.66
Percentage change 5.87	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM XBI VTI IWN VXF IBB DFAC VTWO IWC IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	35.76%	Shs Outstand	54.87M	Perf Week	16.44%
Market Cap	802.30M	Forward P/E	-	EPS next Y	-1.93	Insider Trans	-0.33%	Shs Float	43.31M	Perf Month	79.49%
Income	-101.76M	PEG	-	EPS next Q	-0.41	Inst Own	63.89%	Short Float	26.27%	Perf Quarter	55.15%
Sales	0.00M	P/S	-	EPS this Y	12.20%	Inst Trans	-0.30%	Short Ratio	20.64	Perf Half Y	14.37%
Book/sh	4.87	P/B	2.44	EPS next Y	-12.19%	ROA	-35.25%	Short Interest	11.38M	Perf Year	36.47%
Cash/sh	4.70	P/C	2.53	EPS next 5Y	-	ROE	-38.30%	52W Range	5.27 - 16.65	Perf YTD	29.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.33%	ROI	-30.96%	52W High	-28.53%	Beta	1.00
Dividend TTM	-	Quick Ratio	21.31	Sales past 5Y	0.00%	Gross Margin	-	52W Low	125.81%	ATR (14)	0.71
Dividend Ex-Date	-	Current Ratio	21.31	EPS Y/Y TTM	17.36%	Oper. Margin	0.00%	RSI (14)	73.00	Volatility	6.23% 8.25%
Employees	100	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.11	Target Price	19.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	30.06%	Payout	-	Rel Volume	1.19	Prev Close	11.24
Sales Surprise	-	EPS Surprise	13.79%	Sales Q/Q	-	Earnings	May 06 AMC	Avg Volume	551.19K	Price	11.90
SMA20	26.90%	SMA50	36.08%	SMA200	26.10%	Trades		Volume	658,548	Change	5.87%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform	$8
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$16
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy	$15
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform	$14
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral	$22 → $7
Jul-06-21	Upgrade	Citigroup	Neutral → Buy	$34
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$34
Aug-13-20	Initiated	Robert W. Baird	Outperform	$45
Aug-06-20	Upgrade	Citigroup	Neutral → Buy	$35
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
May-19-20	Initiated	JP Morgan	Overweight	$40
May-19-20	Initiated	Jefferies	Buy	$40
May-19-20	Initiated	Guggenheim	Buy	$45
May-19-20	Initiated	Citigroup	Neutral	$35

Show Previous Ratings

Jul-17-24 11:20AM	ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ (Zacks) -7.01%
Jul-16-24 04:59PM	ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer (GlobeNewswire)
Jul-09-24 07:30AM	Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors (GlobeNewswire) +9.88%
Jul-08-24 06:00PM	Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts? (Insider Monkey) +10.53%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
04:30PM	Loading…
Jul-05-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.68%
May-06-24 09:54PM	ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:15PM	ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC (GlobeNewswire)
Apr-08-24 08:00AM	ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-05-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-04-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Loading…
Mar-26-24 09:55AM	How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3% (Zacks)
Mar-12-24 09:01PM	ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com) +6.35%
Mar-11-24 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Mar-08-24 05:01PM	ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares (GuruFocus.com) -5.78%
Mar-06-24 04:30PM	ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-01-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.07%
Feb-14-24 04:30PM	ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-09-24 02:23AM	ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares (GuruFocus.com)
Feb-08-24 08:50AM	Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why (Zacks)
Feb-02-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-24 03:05PM	Andreas Halvorsen's Viking Global Investors LP Acquires New Stake in ORIC Pharmaceuticals Inc (GuruFocus.com)
Jan-31-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-24 08:50AM	Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-22-24 08:30AM	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing (GlobeNewswire)
12:31PM	Loading…
Jan-09-24 12:31PM	Final Boarding Call: 3 Stocks Set for a Sky-High Surge (InvestorPlace)
Jan-08-24 08:30AM	ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones (GlobeNewswire)
Jan-02-24 04:30PM	ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-23 12:00PM	Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development (GlobeNewswire) -5.30%
Dec-05-23 09:11AM	3 Stocks at the Forefront of Personalized Medicine Trend (InvestorPlace)
Dec-01-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.44%
Nov-06-23 05:22PM	ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com)
04:10PM	ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Nov-03-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-02-23 09:00AM	ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-21-23 07:30AM	Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile (GlobeNewswire)
Oct-17-23 04:30PM	ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023 (GlobeNewswire)
Oct-16-23 12:00PM	Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Oct-06-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-20-23 04:30PM	ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -5.62%
Sep-01-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-23 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates (GlobeNewswire) +10.97%
Aug-04-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-23 01:04PM	Why Shares of Oric Pharmaceuticals Jumped Monday (Motley Fool) +27.73%
08:30AM	ORIC Pharmaceuticals Announces $85 Million Private Placement Financing (GlobeNewswire)
Jun-02-23 04:15PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-31-23 04:10PM	ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-28-23 09:28AM	We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth (Simply Wall St.)
May-08-23 04:05PM	ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
May-05-23 04:15PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-25-23 04:30PM	ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -6.88%
06:35AM	The 7 Best Biotech Stocks for Personalized Medicine Investors (InvestorPlace)
Apr-18-23 04:15PM	ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -6.50%
Mar-31-23 08:40AM	One ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) insider upped their stake by 128% in the previous year (Simply Wall St.)
Mar-29-23 07:53PM	Charts Point to Higher Highs, Says Oppenheimer. Heres a Stock With Over 100% Upside Potential (TipRanks) +5.92% +8.38%
Mar-16-23 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates (GlobeNewswire) +15.24% -8.62%
03:10AM	6 big analyst picks: Stifel says FedEx stock is a buy \| Pro Recap (Investing.com)
Mar-14-23 04:30PM	ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -6.88%
Mar-06-23 04:15PM	ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-03-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.14%
Feb-01-23 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.01%
04:25PM	7 Top Short-Squeeze Candidates to Watch in February (InvestorPlace)
Jan-27-23 08:41AM	ORIC Pharmaceuticals, Inc.'s (NASDAQ:ORIC) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures (Simply Wall St.)
Jan-09-23 08:00AM	ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Jan-03-23 04:30PM	ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-22 11:35AM	ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study (Zacks) +59.67%
08:38AM	Oric's stock rallies on multiple myeloma deal with Pfizer (MarketWatch)
07:54AM	ORIC Pharmaceuticals Shares Move Higher After Equity Infusion, Clinical Collaboration From Pfizer (Benzinga)
Dec-21-22 05:48PM	ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer (GlobeNewswire)
Dec-19-22 08:13AM	Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-13-22 08:00AM	ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +7.76%
Nov-08-22 04:10PM	ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-22 04:05PM	ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update (GlobeNewswire)
Nov-03-22 09:00AM	ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.99%
Oct-22-22 08:36AM	Bullish insiders at ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) loaded up on US$2.1m of stock earlier this year (Simply Wall St.)
Oct-21-22 12:06PM	AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition (Zacks)
Oct-14-22 09:37AM	GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults (Zacks) -11.78%
Oct-13-22 12:51PM	BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance (Zacks)
Oct-07-22 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.80%
10:01AM	Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy (Zacks)
Sep-28-22 01:47PM	Merck's (MRK) Keytruda Gets Four New Approvals in Japan (Zacks)
Sep-22-22 10:50AM	Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks)
Sep-13-22 03:45PM	Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal (Zacks)
08:44AM	Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review (Zacks)
Sep-07-22 01:31PM	IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study (Zacks)
Sep-05-22 10:21AM	Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 (Zacks)
Sep-01-22 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
10:17AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Aug-25-22 11:53AM	AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs (Zacks)
11:52AM	Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down (Zacks)
Aug-23-22 01:53PM	Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe (Zacks)
Aug-20-22 08:28AM	With 61% ownership of the shares, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is heavily dominated by institutional owners (Simply Wall St.)

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kunkel Lori Anne	Director	Jun 03 '24	Option Exercise	3.75	20,500	76,875	20,500	Jun 04 06:48 PM
Chacko Jacob	PRESIDENT AND CEO	Mar 06 '24	Sale	16.21	40,000	648,380	728,544	Mar 08 04:20 PM
Chacko Jacob	PRESIDENT AND CEO	Feb 07 '24	Sale	12.29	26,042	320,186	768,544	Feb 08 08:01 PM
Chacko Jacob	PRESIDENT AND CEO	Feb 06 '24	Sale	12.12	13,958	169,160	794,586	Feb 08 08:01 PM
Multani Pratik S	Chief Medical Officer	Dec 15 '23	Option Exercise	0.00	14,042	0	29,091	Dec 19 07:42 PM
Chacko Jacob	President and CEO	Dec 15 '23	Option Exercise	0.00	38,667	0	823,083	Dec 19 07:39 PM
Chacko Jacob	President and CEO	Dec 15 '23	Sale	8.58	14,539	124,813	808,544	Dec 19 07:39 PM
Multani Pratik S	Chief Medical Officer	Dec 15 '23	Sale	8.59	5,282	45,351	23,809	Dec 19 07:42 PM
Piscitelli Dominic	Chief Financial Officer	Dec 15 '23	Sale	8.58	5,282	45,338	83,809	Dec 19 07:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORIC

ORIC Pharmaceuticals Inc

Upgrade your FINVIZ experience